Paliperidone palmitate

棕榈酸帕利哌酮

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NamePaliperidone palmitate
Drug Alias Name棕榈酸酯帕利哌酮棕榈酸帕潘立酮棕榈帕利哌酮酯Invega TrinzaTrevicta +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizoaffective disorderSchizophrenia
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryUnited States
Original Approved Date2009/07/31
Country/TerritoryCzechiaBelgiumBulgaria +[49] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJanssen-Cilag International NvJanssen Pharmaceuticals IncJanssen Pharmaceutical Kk +[5] 
Inactive CompaniesJanssen Pharmaceutica NVJanssen-Cilag Farmaceutica LtdaXian Janssen Pharmaceutical Ltd +[8] 
Active IndicationsSchizophrenia
Inactive IndicationsSchizoaffective disorder

Other Information

ATC CodeN05AX13
Related LinksWikipediaDrugBankKEGG